GH Stock Recent News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from pred.

Starting in 2014, and even more notably in 2016 as Warren Buffett himself chipped in, Apple (NASDAQ: AAPL) became the benchmark company, and investors around the world were trying to find the ‘next Apple.'

GH can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield's strongest adherence rate, with the potential for on-par sensitivity submission within 18 months will drive adoption. Currently trading over 1.5 STD below historical discount to Exact Sciences (EXAS), their main comp.

While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by major indices such as the S&P 500 and the Dow Jones Industrial Average (DJIA) which have been running close to record highs with generally favorable forecasts.

Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York Fireside Chat on Thursday, February 29 at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time TD Cowen 44th Annual Health Care Conference in Boston Fireside Chat on Tuesday, March 5 at 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time Intere.